Published in Am J Med on October 01, 2003
Patient- and Physician-Based Osteoporosis Education | NCT00073190
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
Quality of osteoporosis care of older Medicare recipients with fragility fractures: 2006 to 2010. J Am Geriatr Soc (2013) 2.08
Racial and socioeconomic disparities in bone density testing before and after hip fracture. J Gen Intern Med (2007) 1.17
Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc (2010) 1.16
Postfracture care for older women: gaps between optimal care and actual care. Can Fam Physician (2008) 1.11
Osteoporosis management among residents living in long-term care. Osteoporos Int (2009) 1.07
Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med (2007) 0.98
Characteristics of elderly patients admitted to an urban tertiary care hospital with osteoporotic fractures: correlations with risk factors, fracture type, gender and ethnicity. Osteoporos Int (2005) 0.98
Patient and physician predictors of post-fracture osteoporosis management. J Gen Intern Med (2008) 0.95
Prevention and clinical management of hip fractures in patients with dementia. Geriatr Orthop Surg Rehabil (2010) 0.94
Women with hip fracture have a greater rate of decline in bone mineral density than expected: another significant consequence of a common geriatric problem. Osteoporos Int (2006) 0.93
Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey. Osteoporos Int (2005) 0.93
Development of an integrated-care delivery model for post-fracture care in Ontario, Canada. Osteoporos Int (2006) 0.91
Correlates of use of antifracture therapy in older women with low bone mineral density. J Gen Intern Med (2006) 0.88
Once-yearly zoledronic acid in hip fracture prevention. Clin Interv Aging (2009) 0.86
Predictors of very low adherence with medications for osteoporosis: towards development of a clinical prediction rule. Osteoporos Int (2010) 0.86
Improving osteoporosis care in high-risk home health patients through a high-intensity intervention. Contemp Clin Trials (2011) 0.83
Access to bone mineral density testing in patients at risk for osteoporosis. Osteoporos Int (2006) 0.82
Patterns of Prescription Drug Use Before and After Fragility Fracture. JAMA Intern Med (2016) 0.81
High-risk patients' readiness to undergo BMD testing for osteoporosis diagnosis in Pennsylvania. Int Q Community Health Educ (2009) 0.81
Clinical prognosis, pre-existing conditions and the use of reperfusion therapy for patients with ST segment elevation acute myocardial infarction. Can J Cardiol (2006) 0.81
Fractal lacunarity of trabecular bone and magnetic resonance imaging: New perspectives for osteoporotic fracture risk assessment. World J Orthop (2015) 0.80
Effect of the women's health initiative on prescription anti-osteoporosis medication utilization. Osteoporos Int (2008) 0.79
The effect of a fracture protocol on hospital prescriptions after minimal trauma fractured neck of the femur: a retrospective audit. Osteoporos Int (2005) 0.79
It is time for everyone to own the bone. Osteoporos Int (2011) 0.78
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis. Ther Clin Risk Manag (2009) 0.77
Addition of a fracture risk assessment to a coordinator's role improved treatment rates within 6 months of screening in a fragility fracture screening program. Osteoporos Int (2016) 0.77
A new diagnostic score to detect osteoporosis in patients undergoing lumbar spine MRI. Eur Radiol (2015) 0.76
Vitamin D supplementation in fractured patient: how, when and why. Clin Cases Miner Bone Metab (2009) 0.76
Evaluation of Patients' Response Toward Osteoporosis Letter Intervention Versus Phone Call Plus Letter Intervention. Geriatr Orthop Surg Rehabil (2015) 0.75
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum (2008) 19.80
Variable selection for propensity score models. Am J Epidemiol (2006) 10.68
A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol (2005) 8.77
Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med (2005) 8.44
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum (2003) 6.68
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57
A randomized study of how physicians interpret research funding disclosures. N Engl J Med (2012) 5.47
Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med (2014) 4.99
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
Development of the QuickDASH: comparison of three item-reduction approaches. J Bone Joint Surg Am (2005) 4.90
The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One (2010) 4.75
Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. Arch Intern Med (2004) 4.68
Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51
Rates and outcomes of primary and revision total hip replacement in the United States medicare population. J Bone Joint Surg Am (2003) 4.38
New FDA breakthrough-drug category--implications for patients. N Engl J Med (2014) 4.30
The importance of patient expectations in predicting functional outcomes after total joint arthroplasty. J Rheumatol (2002) 4.16
Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 4.16
A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol (2011) 3.98
Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should. AIDS (2010) 3.93
Use of antidepressants near delivery and risk of postpartum hemorrhage: cohort study of low income women in the United States. BMJ (2013) 3.88
Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA (2010) 3.85
Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab (2002) 3.85
Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med (2009) 3.84
Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol (2007) 3.82
The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med (2010) 3.78
Predicting the outcome of total knee arthroplasty. J Bone Joint Surg Am (2004) 3.70
Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res (2006) 3.66
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med (2006) 3.64
Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med (2014) 3.62
Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ (2013) 3.43
The quality of pharmacologic care for vulnerable older patients. Ann Intern Med (2004) 3.34
Incidence rates of dislocation, pulmonary embolism, and deep infection during the first six months after elective total hip replacement. J Bone Joint Surg Am (2003) 3.33
Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol (2005) 3.33
Timing of total joint replacement affects clinical outcomes among patients with osteoarthritis of the hip or knee. Arthritis Rheum (2002) 3.29
The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med (2011) 3.27
Rethinking the use of physicians as hired expert lecturers. Ann Intern Med (2014) 3.22
Group exercise, education, and combination self-management in women with fibromyalgia: a randomized trial. Arch Intern Med (2007) 3.20
Drug-review deadlines and safety problems. N Engl J Med (2008) 3.16
Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med (2013) 3.13
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation (2009) 3.09
Balancing innovation, access, and profits--market exclusivity for biologics. N Engl J Med (2009) 3.08
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.04
The dramatic increase in total knee replacement utilization rates in the United States cannot be fully explained by growth in population size and the obesity epidemic. J Bone Joint Surg Am (2012) 2.98
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation (2004) 2.98
University-based science and biotechnology products: defining the boundaries of intellectual property. JAMA (2005) 2.95
Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91
Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med (2002) 2.85
Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med (2002) 2.82
Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol (2006) 2.81
Internet marketing of herbal products. JAMA (2003) 2.77
Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA (2004) 2.77
Trends in epidemiology of knee arthroplasty in the United States, 1990-2000. Arthritis Rheum (2005) 2.76
Revising expectations from rapid HIV tests in the emergency department. Ann Intern Med (2008) 2.74
Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol (2010) 2.74
Accuracy of Medicare claims data for rheumatologic diagnoses in total hip replacement recipients. J Clin Epidemiol (2003) 2.72
Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA (2010) 2.71
Sending pharma better signals. Science (2005) 2.69
Epidemiology of total knee replacement in the United States Medicare population. J Bone Joint Surg Am (2005) 2.67
Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis (2005) 2.65
Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res (2003) 2.65
Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA (2011) 2.60
Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol (2008) 2.58
Performance of propensity score calibration--a simulation study. Am J Epidemiol (2007) 2.56
Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol (2005) 2.55
Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab (2003) 2.54
Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med (2015) 2.53
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med (2004) 2.52
Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab (2003) 2.47
Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation (2008) 2.42
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med (2008) 2.40
Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology (2005) 2.38
Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.37
Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med (2011) 2.35
Racial differences in screening for prostate cancer in the elderly. Arch Intern Med (2004) 2.34
Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care (2007) 2.31
Arthritis self-management education programs: a meta-analysis of the effect on pain and disability. Arthritis Rheum (2003) 2.30
Rotator cuff disorders: recognition and management among patients with shoulder pain. Arthritis Rheum (2004) 2.28
Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther (2011) 2.24
Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum (2007) 2.18
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer (2008) 2.16
Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol (2002) 2.15
Bone density screening intervals for osteoporosis: one size does not fit all. JAMA (2012) 2.14